Phosphate Binders Market Demand Analysis, Type, Statistics, Regions and Forecast - 2031
The global phosphate binders’ market is expected to grow at a significant CAGR during the forecast period (2024-2031). Cardiovascular diseases and diabetes lead to common complications such as nephrology and urology disorders. Unhealthy food habits and drugs are known to cause nephrological and urological diseases. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 26 million people have chronic kidney diseases in the US. The statistics show that about 87,000 patients die due to kidney failure every year. Commonly used drug classes for treating nephrological and urological disorders include diuretics, anti-hypertensive drugs, phosphate binders, and anti-cholinergic and 5-alpha-reductase inhibitors.
Get Free Sample link @ https://www.omrglobal.com/request-sample/phosphate-binders-market
Phosphate binders are drugs that are used to lower the absorption of phosphate in patients suffering from chronic renal failure due to their inability to remove phosphorus naturally. Excess deposition of phosphorus in the body, especially in a kidney failure patient, results in the depletion of calcium from bones and ultimately leads to diseases such as hyperphosphatemia and renal osteodystrophy or renal bone. Phosphate binders work by binding phosphate in the gastrointestinal tract, ultimately making it unavailable to the body for absorption. In June 2014, Keryx Biopharmaceuticals, Inc. received patent for Zerenex, a ferric citrate-based phosphate binder, which will expire in 2024. The company has filed a new drug application (NDA) for Zerenex and is currently under review by the US FDA. Sanofi lost its patent for Renvela (sevelamer) in 2014; the drug generated total revenue of $750 million in 2013. Other key drugs in the market include Alucap (aluminum hydroxide) by Meda Pharma, Calcichew (calcium carbonate), Renagel (sevelamer) by Genzyme Corp., and Fosrenol (lanthanum carbonate) by Shire US, Inc.
The increased frequency of chronic renal disease is propelling the global phosphate binding agents market. Chronic renal disease affects approximately 20 million people in the US, and its prevalence is quickly increasing among adults over the age of 65. The use of these phosphate binding agents in hyperphosphatemia caused by chronic kidney disease has been approved by the FDA. Furthermore, increased awareness of the problems associated with chronic kidney disease and treatment choices is propelling the global phosphate binders market.
Full report of Phosphate Binders Market available @ https://www.omrglobal.com/industry-reports/phosphate-binders-market
Market Coverage
Competitive Landscape: Sanofi S.A., Baxter International Inc., and Opko Health, among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Phosphate Binders Market Report Segmentation
By Type
By Application
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/phosphate-binders-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.